Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.38 |
| ▸ | CXCR3 | P49682 | 3/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5136708 | 0.98 | C5AR1 (0.45) | C5AR1KCNH2TSHRCHRM5CHRM1 | |
| SCHEMBL1912862 | 0.96 | C5AR1 (0.49) | C5AR1KCNH2TSHRCHRM5CHRM1 | |
| SCHEMBL5135014 | 0.95 | C5AR1 (0.54) | C5AR1KCNH2TSHRCHRM5CHRM1 | |
| SCHEMBL5137871 | 0.91 | C5AR1 (0.39) | C5AR1KCNH2CHRM5CHRM1CXCR3 | |
| SCHEMBL1912837 | 0.90 | C5AR1 (0.55) | C5AR1TSHRHSD11B1 | |
| SCHEMBL5137683 | 0.88 | C5AR1 (0.53) | C5AR1TSHRHSD11B1 | |
| SCHEMBL5178967 | 0.86 | C5AR1 (0.45) | C5AR1KCNH2TSHR | |
| SCHEMBL647999 | 0.86 | C5AR1 (0.62) | C5AR1TSHR | |
| SCHEMBL5137517 | 0.85 | C5AR1 (0.50) | C5AR1TSHRHSD11B1 | |
| SCHEMBL5134857 | 0.84 | C5AR1 (0.60) | C5AR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |